Skip to Content
Søk Menu

ESMO20: First new drug in years reduces recurrence in high-risk hormone receptor positive early breast cancer

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Hope Rugo

Abemaciclib Shows Significant Benefit for HR-Positive HER2-Negative Patients with Advanced Breast Cancer

/ Hope S. Rugo
Brystkreft Play the Video 11:57
Maren Marie Andreassen

MRI-Based AI Can Detect Responsive Treatment of Breast Cancer After Three Weeks of Therapy

/ Maren Marie Andreassen
BrystkreftNBCN Play the Video 02:20
Adam Brufsky

SABCS 2024: Palbociclib, Abemaciclib, and Ribociclib Can Be Considered Equivalent in the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer

/ Adam Brufsky
BrystkreftSABCS24 Play the Video 08:56
Stefania Katrin Finnsdottir

The Need to Improve Compliance with Adjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer

/ Stefanía Katrín Finnsdóttir
BrystkreftNBCN Play the Video 02:45
Minna Tanner

The Approval of New Drugs Should Be Harmonized Across the Nordic Countries

/ Minna Tanner
BrystkreftNBCN Play the Video 03:20
Niklas Loman

We Can Be Proud of What We Have Achieved in the Nordic Breast Cancer Research

/ Niklas Loman
BrystkreftNBCN Play the Video 02:52
Hege Elisabeth Giercksky Russnes

Nordic Pathologists Unite for Advancements in Breast Cancer Care

/ Hege Elisabeth Giercksky Russnes
BrystkreftNBCN Play the Video 01:24
Birgitte Vrou Offersen

New Nordic Breast Cancer Network Boosts Collaboration on Radiotherapy

/ Birgitte Vrou Offersen
BrystkreftNBCN Play the Video 02:17

Towards a Stronger and Unified Nordic Region in Breast Cancer Research and Treatment

/ BestPractice Nordic
BrystkreftNBCN
Back to top